A new observational study that analyzed a World Health Organization database that tracks suspected adverse drug reactions found that there was a greater rate of reports of suicidal thoughts associated with semaglutide, the ingredient in Novo Nordisk’s (NVO) Ozempic and Wegovy, compared with other drugs in the database. The study, published in JAMA Network Open, does not mean that semaglutide caused suicidal thoughts, and the overall rate of those thoughts occurring was still small, making up only 0.3% of all the adverse reactions reported for semaglutide, but a summary of the “Conclusions and Relevance” on the JAMA site stated: “This study using the WHO database found a signal of semaglutide-associated suicidal ideation, which warrants urgent clarification.” Semaglutide, or Ozempic, and tirzepatide, or Mounjaro, which is marketed by Eli Lilly (LLY), are both injectable GLP-1 drugs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk price target raised to DKK 1,013 from DKK 992 at Guggenheim
- Novo Nordisk Initiates Multi-Billion Share Buyback
- Healthcare Stocks Rise despite Medicare Price Cuts for Their Drugs
- Is Berkshire Hathaway (NYSE:BRK.B) Missing Out on AI Tailwinds?
- U.S. to announce prices for drugs in Medicare negotiations, NY Times says